Vatelizumab is a humanised monoclonal antibody targeting Integrin alpha2beta1 (very late antigen 2, VLA-2, CD49b), which enhances the frequency of regulatory T cells via the p38 MAPK signalling pathway and can be used for research into multiple sclerosis.
Purity:
99.54%
CAS Number:
[1238217-55-4]
Target:
Integrin
* VAT and and shipping costs not included. Errors and price changes excepted
